Sarina Piha-Paul, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

SarinaAnnePiha-PaulMD

Oncology Houston, TX

Hematologic Oncology

Associate Professor, Phase I Fellowship Program Director

Dr. Piha-Paul is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Piha-Paul's full profile

Already have an account?

Education & Training

  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterFellowship, Hematology/Oncology, 2006 - 2009
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 2002 - 2006
  • Louisiana State University School of Medicine in New Orleans
    Louisiana State University School of Medicine in New OrleansClass of 2002

Certifications & Licensure

  • OK State Medical License
    OK State Medical License 2020 - 2021
  • TX State Medical License
    TX State Medical License 2008 - 2021

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/re... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Join now to see all

Press Mentions

  • Signature Trial Program Aims for Rapid Delivery of Novel Therapies
    Signature Trial Program Aims for Rapid Delivery of Novel TherapiesAugust 05, 2016 10:49

Professional Memberships

Hospital Affiliations